Skip to main content
SpringerLink
Log in

Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma

  • Chapter
  • First Online:
The Glaucoma Book

Abstract

The medical management of glaucoma is often compromised by patients’ nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi­cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57% progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Pang I, unpublished observation.

  2. 2.

    Clark AF, unpublished observation.

References

  1. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2:1031–1033.

    Article  CAS  PubMed  Google Scholar 

  2. Norell S. Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma. Acta Ophthalmol Suppl (Copenh). 1980;143:1–28.

    Google Scholar 

  3. Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol. 1980;64:134–141.

    Article  Google Scholar 

  4. Norell SE, Granstrom PA, Wassen R. A medication monitor and fluorescein technique designed to study medication behaviour. Acta Ophthalmol (Copenh). 1980;58:459–467.

    Article  CAS  Google Scholar 

  5. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524–530.

    CAS  PubMed  Google Scholar 

  6. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523.

    CAS  PubMed  Google Scholar 

  7. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–480.

    Article  CAS  PubMed  Google Scholar 

  8. Kholdebarin R, Campbell RJ, Jin Y, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–461.

    Article  PubMed  Google Scholar 

  9. Brown M, Brown G, Spaeth G. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol. 1984;19(1):2–5.

    CAS  PubMed  Google Scholar 

  10. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052–5057.

    Article  PubMed  Google Scholar 

  11. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114:648–652.

    Article  PubMed  Google Scholar 

  12. Robin AL, Novack GD, Covert DW, Crockett S, Marcic T. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540.

    Article  PubMed  Google Scholar 

  13. Robin AL, Stone JL, Sleath B, Covert DW, Cagle GD. An Objective Evaluation in Glaucoma Patients of Eye-Drop Instillation Using Video Observations and Patient Surveys. Abstract presented at American Glaucoma Society Annual meeting, Washington DC, March 2008.

    Google Scholar 

  14. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–398.

    Article  PubMed  Google Scholar 

  15. Nordstrom BL, Friedman DS, Mozafarri E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.

    PubMed  Google Scholar 

  16. Covert D, Robin AL, Novack GD. Letter to the editor. Systemic medications and glaucoma patients. Ophthalmology. 2005;112(10):1849–1850.

    Article  PubMed  Google Scholar 

  17. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971–976.

    Article  CAS  PubMed  Google Scholar 

  18. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–868.

    Article  PubMed  Google Scholar 

  19. Patel SC, Spaeth G. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 2005;26(3):233–236.

    Google Scholar 

  20. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.

    Article  PubMed  Google Scholar 

  21. Urquhart J. The drugs not taken. Science. 2008;321(5890):769.

    Article  PubMed  Google Scholar 

  22. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.

    Article  PubMed  Google Scholar 

  23. Tsai T, Robin AL, Smith JP. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29–35.

    PubMed  Google Scholar 

  24. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836–837.

    Article  PubMed  Google Scholar 

  25. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915–922.

    CAS  PubMed  Google Scholar 

  26. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899.

    Article  CAS  PubMed  Google Scholar 

  27. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990;97:1423–1427.

    CAS  PubMed  Google Scholar 

  28. Augustin AJ, D’Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):9–12.

    Article  CAS  PubMed  Google Scholar 

  29. Augustin A. Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237–246.

    Article  CAS  PubMed  Google Scholar 

  30. Russell SR, Hudson HL, Jerdan JA, Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration - a review of clinical outcomes. Surv Ophthalmol. 2007;52(suppl 1):S79-S90.

    Article  PubMed  Google Scholar 

  31. Clark AF, Wilson K, deKater AW, Allingham RR, McCartney MD. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995;36:478–489.

    CAS  PubMed  Google Scholar 

  32. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783–793.

    Article  CAS  PubMed  Google Scholar 

  33. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2): 275–284.

    Article  CAS  PubMed  Google Scholar 

  34. Robin AL, Clark AF, Covert D, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45–50.

    Article  CAS  PubMed  Google Scholar 

  35. Prata TS, Tavares IM, Mello PAA, Tamura CY, Belfort R Jr. Anterior juxtascleral depot of anecortave acetate: intraocular pressure reduction in different types of glaucoma. Association for Research in Vision and Ophthalmology (ARVO); abstract 2008 E-1205, poster A47.

    Google Scholar 

  36. Callanan D, Fuller C, Landry TA, Dickerson JE, Bergamini MVW. Prophylactic anecortave acetate in patients with a retisert implant. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 2008 E-5630.

    Google Scholar 

  37. Landry TA, Dickerson J, Merriam JC. The use of anecortave acetate for refractory, complex glaucoma. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 1206/A48.

    Google Scholar 

  38. Robin AL, Suan EP, Sjaarda RN, Callanan DG, DeFaller J. Anecortave acetate lowers intraocular pressure in eyes with steroid injection-related glaucoma. Arch Ophthalmol. 2009;127:173–178.

    Article  PubMed  Google Scholar 

  39. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24–27.

    Article  CAS  PubMed  Google Scholar 

  40. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593–598.

    Article  PubMed  Google Scholar 

  41. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26(4):277–281.

    Article  CAS  PubMed  Google Scholar 

  42. Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053–1060.

    CAS  PubMed  Google Scholar 

  43. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650–656.

    CAS  PubMed  Google Scholar 

  44. Solomon A, Ticho U, Frucht-Pery J. Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. J Ocul Pharmacol Ther. 1999;15(4):283–293.

    Article  CAS  PubMed  Google Scholar 

  45. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297–300.

    CAS  PubMed  Google Scholar 

  46. Ashkenazi I, Melamed S, Avni I, Bartov E, Blumenthal M. Risk factors associated with late infection of filtering blebs and endophthalmitis. Ophthalmic Surg. 1991;22(10):570–574.

    CAS  PubMed  Google Scholar 

  47. Phillips WB 2nd, Wong TP, Bergren RL, Friedberg MA, Benson WE. Late onset endophthalmitis associated with filtering blebs. Ophthalmic Surg. 1994;25(2):88–91.

    PubMed  Google Scholar 

  48. Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma. 2000;9(6):438–443.

    CAS  PubMed  Google Scholar 

  49. Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354–369.

    CAS  PubMed  Google Scholar 

  50. Gottanka J, Chan D, Eichhorn M, Lutjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in persued human eyes. Invest Ophthalmol Vis Sci. 2004;45:153–158.

    Article  PubMed  Google Scholar 

  51. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in the human trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci. 2006;47:226–234.

    Article  PubMed  Google Scholar 

  52. Clark AF, Millar C, Pang I-H, Jacobson N, Shepard AR. Adenoviral gene transfer of active human transforming growth factor-b2 induces elevated intraocular pressure in rats. 2006 Annual Meeting Association for Research in Vision and Ophthalmology. Abstract 4771.

    Google Scholar 

  53. Shepard AR, Millar JC, Pang IH, Jacobson N, Clark AF. Adenoviral gene transfer of active human transforming factor-b2 elevates intraocular pressure and reduces outflow facility in rodent eyes. In press.

    Google Scholar 

  54. Fleenor DL, Pang I-H, Clark AF. Regulation of PAI-1 protein in human trabecular meshwork cells. 2008 Annual Meeting Association for Research in Vision and Ophthalmology (ARVO), Abstract 1631.

    Google Scholar 

  55. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67(9):1937–1944.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Amy Lewis Hennessy MD, MPH

  2. Department of Ophthalmology/Glaucoma, Greater Baltimore Medical Center, Baltimore, MA, USA

    Amy Lewis Hennessy MD, MPH

  3. International Health, Bloomberg School of Public Health, Wilmer Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Alan L. Robin MD

Authors
  1. Amy Lewis Hennessy MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan L. Robin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2889 10th Avenue, N., Palm Springs, 33461, USA

    Paul N. Schacknow

  2. Casey Eye Institute, Dept. Ophthalmology, Oregon Health & Sciences University, SW. Terwilliger Blvd. 3375, Portland, 97201-4197, USA

    John R. Samples

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hennessy, A.L., Robin, A.L. (2010). Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma. In: Schacknow, P., Samples, J. (eds) The Glaucoma Book. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76700-0_89

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-76700-0_89

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-76699-7

  • Online ISBN: 978-0-387-76700-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation